Last reviewed · How we verify
OCS-01
OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor.
OCS-01 is an anti-vascular endothelial growth factor (VEGF) inhibitor. Used for Treatment of neovascular (wet) age-related macular degeneration.
At a glance
| Generic name | OCS-01 |
|---|---|
| Also known as | dexamethasone ophthalmic suspension eye drops |
| Sponsor | Oculis |
| Drug class | anti-VEGF inhibitor |
| Target | VEGF |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
It works by binding to VEGF and preventing its interaction with its receptor, thereby inhibiting angiogenesis and reducing vascular permeability. This mechanism is thought to be beneficial in treating conditions characterized by excessive angiogenesis, such as age-related macular degeneration.
Approved indications
- Treatment of neovascular (wet) age-related macular degeneration
Common side effects
- Conjunctival hemorrhage
- Eye pain
- Increased intraocular pressure
Key clinical trials
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1) (PHASE2, PHASE3)
- A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 2) (PHASE3)
- OCS-01 in Treating Inflammation and Pain in Post-cataract Patients (PHASE2)
- A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery (PHASE3)
- Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema (PHASE2)
- Study Evaluating the Efficacy and Safety of OCS-01 Eye Drops in Subjects Following Cataract Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |